Latest articles and price-sensitive announcements with AI sentiment classification.
Entropy Neurodynamics signs a pre-Clinical Trial Agreement with the University of California, San Francisco (UCSF) to undertake a Phase II ... Read More The post Entropy’s IV-psilocin candidate will go up against widely used antidepressant in proposed Phase II trial appeared first on Stockhead.
other announcement
The deal gives a key manufacturing base as it prepares for broader international trials, regulatory pathways and potential commercialisation. ... Read More The post StockTake: Entropy locks in BioCina for TRP-8803 GMP manufacturing appeared first on Stockhead.
other announcement
ENP's basket study will test TRP-8803 across multiple neuropsychiatric disorders in one clinical program. ... Read More The post Long Shortz with Entropy Neurodynamics: Treatment trial fast-tracked appeared first on Stockhead.
director_dealing announcement
ENP has signed an expanded clinical trial research agreement with Melbourne’s Swinburne University to conduct the study. ... Read More The post Entropy secures ethics approval for ‘world-first’ multi-indication psychedelic trial appeared first on Stockhead.
Entropy Neurodynamics (ASX:ENP): TRP-8803 Clinical Trial Advances Kalkine
other announcement
The patent titled Methods of Treating Fibromyalgia with Compositions Comprising Psilocybin, provides protection for the clinical use of psilocybin in ... Read More The post Entropy granted South African patent for psilocybin-based fibromyalgia treatment appeared first on Stockhead.
other announcement
TRP8803 used in trials to treat-resistant binge eating disorder why IV-delivered psilocybin approach could transform psychedelic medicine. ... Read More The post Long Shortz with Entropy Neurodynamics: Phase Two results exceed expectations appeared first on Stockhead.
Entropy Neurodynamics (ASX:ENP): Could These World-First IV Psilocin Results Be Breakthrough Moment? Kalkine
other announcement
Entropy Neurodynamics hopes that an expected FDA breakthrough drug approval for depression will pave the way for its own psychedelic ... Read More The post Biocurious: Entropy surfs the supportive wave to psychedelic drug approval appeared first on Stockhead.
Entropy Neurodynamics hopes that an expected FDA breakthrough drug approval for depression will pave the way for its own psychedelic ... Read More The post Biocurious: Entropy rides a supportive wave towards psychedelic drug approval appeared first on Stockhead.
Safety gatekeepers have cleared Entropy Neurodynamics to advance to the second cohort of its psilocin-assisted binge eating disorder study. ... Read More The post Ever so safely, Entropy can kick off second stage of groundbreaking binge eating trial appeared first on Stockhead.
Entropy Neurodynamics (ASX:ENP) Shares Slip Despite DSMB Safety Clearance — What Do Investors Need to Know? Kalkine
director_dealing announcement
other announcement
Phase 2a trial enrolled 12 patients who had failed multiple standard treatments. ... Read More The post Entropy Neurodynamics reports 75pc response rate in IBS trial appeared first on Stockhead.
other announcement
director_dealing announcement
other announcement
other announcement
director_dealing announcement
Stockhead
ASX
Small Caps
Google News